New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 19, 2013
11:55 EDTODP, TMO, PPHM, FE, RIGLHigh option volume stocks: FE TMO RIGL PPHM ODP
News For FE;TMO;RIGL;PPHM;ODP From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
February 27, 2015
10:52 EDTODPOptions with increasing implied volatility
Options with increasing implied volatility: WBAI ARCP BHI TLM ODP
February 24, 2015
06:55 EDTODPOffice Depot sees $400M of cash merger integration expenses from 2014-2016
Subscribe for More Information
06:54 EDTODPOffice Depot expects to achieve synergy benefits of more than $750M by 2016-end
Subscribe for More Information
06:53 EDTODPOffice Depot sees FY15 sales to be lower than FY14, consensus $15.5B
Subscribe for More Information
06:52 EDTODPOffice Depot says acquisition by Staples to close by end of 2015
06:52 EDTODPOffice Depot reports Q4 N. American retail division sales $1.54B
Subscribe for More Information
06:51 EDTODPOffice Depot says 2015 operating priorities focus on synergies, efficiencies
Subscribe for More Information
06:51 EDTODPOffice Depot reports Q4 adjusted EPS 7c, consensus 4c
Reports Q4 revenue $3.83B, consensus $3.91B
February 23, 2015
13:34 EDTFEJCP&L plans to spend $267M in 2015 to enhance electric system
Subscribe for More Information
12:21 EDTRIGLOn The Fly: Midday Wrap
Subscribe for More Information
09:25 EDTRIGLOn The Fly: Pre-market Movers
Subscribe for More Information
08:15 EDTRIGLRigel Pharmaceuticals and Bristol-Myers announces R&D collaboration agreement
Rigel Pharmaceuticals (RIGL) and Bristol-Myers (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigel's extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune system's activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibb's Opdivo and Yervoy. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigel's TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
08:06 EDTRIGLBristol-Myers, Rigel enter R&D agreement for TGF beta receptor kinase inhibitors
Rigel Pharmaceuticals (RIGL) and Bristol-Myers Squibb (BMY) announced that they have entered into a collaboration agreement for the discovery, development and commercialization of cancer immunotherapies based on Rigelís extensive portfolio of small molecule TGF beta receptor kinase inhibitors. TGF beta can promote tumor growth, broadly suppress the immune system and increase the ability of tumors to spread in the body. The collaboration will focus on developing a new class of therapeutics aimed at increasing the immune systemís activity against various cancers either as monotherapy or in combination with immune checkpoint inhibitors, including Bristol-Myers Squibbís Opdivo, or nivolumab, and Yervoy, or ipilimumab. Under the terms of the agreement, Bristol-Myers Squibb will obtain exclusive, worldwide rights to develop and commercialize small molecule therapeutics derived from Rigelís TGF beta library, including, but not limited to, those approved to treat cancer. Bristol-Myers Squibb will pay $30M upfront and Rigel will be eligible to receive development and regulatory milestones that could total more than $309M for a successful compound approved in multiple indications. Rigel will also be eligible to receive tiered royalties on the net sales of any products from the collaboration.
07:37 EDTFECredit Suisse to hold a summit
Subscribe for More Information
February 20, 2015
10:20 EDTFEHigh option volume stocks
Subscribe for More Information
February 17, 2015
16:32 EDTFEFirstEnergy sees FY15 EPS $2.40-$2.70 , consensus $2.79
16:31 EDTFEFirstEnergy reports Q4 EPS 80c, consensus 76c
Fourth quarter 2014 operating earnings primarily reflect a lower effective tax rate, lower operating expenses and increased transmission revenues, partially offset by lower commodity margin at the competitive business, higher interest expense, and higher depreciation.
16:20 EDTTMOThermo Fisher announces CFO Peter Wilver resignation plan
Subscribe for More Information
15:32 EDTFENotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Devon Energy (DVN), consensus $1.05... Vornado Realty (VNO), consensus $1.23... Analog Devices (ADI), consensus 61c... FirstEnergy (FE), consensus 75c... CF Industries (CF), consensus $5.08... Agilent Technologies (A), consensus 41c... Cimarex Energy (XEC), consensus 82c... Flowserve (FLS), consensus $1.13... Fossil (FOSL), consensus $3.07... Rackspace (RAX), consensus 19c... Norwegian Cruise Line (NCLH), consensus 37c... Jack in the Box (JACK), consensus 87c... Cloud Peak Energy (CLD), consensus 7c... La-Z-Boy (LZB), consensus 38c... KAR Auction Services (KAR), consensus 29c... Owens & Minor (OMI), consensus 50c... Valmont Industries (VMI), consensus $1.65... Realty Income (O), consensus 66c.
13:18 EDTTMOOmega Advisors gives quarterly update on stakes
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use